Arginine and methylated arginines in human plasma and urine measured by tandem mass spectrometry without the need for chromatography or sample derivatisation.

[1]  H. Gehring,et al.  Protein arginine methylation: Cellular functions and methods of analysis. , 2006, Biochimica et biophysica acta.

[2]  J. Cooke,et al.  Symmetric dimethylarginine (SDMA) as endogenous marker of renal function--a meta-analysis. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[3]  E. Schwedhelm,et al.  Determination of NG,NG-dimethyl-L-arginine, an endogenous NO synthase inhibitor, by gas chromatography-mass spectrometry. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[4]  P. Vallance,et al.  Cardiovascular Biology of the Asymmetric Dimethylarginine:Dimethylarginine Dimethylaminohydrolase Pathway , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[5]  D. Tsikas,et al.  Quantitative determination of circulating and urinary asymmetric dimethylarginine (ADMA) in humans by gas chromatography-tandem mass spectrometry as methyl ester tri(N-pentafluoropropionyl) derivative. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[6]  R. Böger.  The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. , 2003, Cardiovascular research.

[7]  Yizeng Liang,et al.  Rapid simultaneous determination of arginine and methylated arginines in human urine by high-performance liquid chromatography–mass spectrometry , 2003 .

[8]  R. Testa,et al.  High-performance liquid chromatographic assay of asymmetric dimethylarginine, symmetric dimethylarginine, and arginine in human plasma by derivatization with naphthalene-2,3-dicarboxaldehyde. , 2003, Analytical biochemistry.

[9]  T. Annesley.  Ion suppression in mass spectrometry. , 2003, Clinical chemistry.

[10]  P. Tsao,et al.  Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. , 2002, JAMA.

[11]  J P Cooke,et al.  Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. , 2001, The American journal of cardiology.

[12]  P. Vallance,et al.  Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. , 1999, Cardiovascular research.

[13]  S. Nussey,et al.  Plasma concentrations of asymmetric dimethylarginine, a natural inhibitor of nitric oxide synthase, in normal pregnancy and preeclampsia. , 1998, American journal of obstetrics and gynecology.

[14]  S. Bode-Böger,et al.  Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits. , 1996, Biochemical and biophysical research communications.

[15]  Y. Kakimoto,et al.  Isolation and Identification of Ng,Ng- and Ng,N'g-Dimethylarginine, Nε-Mono-, Di-, and Trimethyllysine, and Glucosylgalactosyl- and Galactosyl-δ-hydroxylysine from Human Urine , 1970 .

[16]  G. Junk,et al.  The Mass Spectra of the α-Amino Acids , 1963 .

[17]  J. L. Corbin,et al.  NG-methylated arginines; A convenient preparation of NG-methylarginine☆ , 1974 .